The Glucocorticoid Resistance Syndrome. Two Cases of a Novel Pathogenic Variant in the Glucocorticoid Receptor Gene.

JCEM Case Rep

Biochemistry and Molecular Genetics Department, CDB, Hospital Clínic de Barcelona, Faculty of Medicine, University of Barcelona, 08036 Barcelona, Spain.

Published: January 2024

Glucocorticoid resistance syndrome is a rare genetic condition characterized by generalized or partial target-tissue insensitivity to glucocorticoids and a consequent hyperactivation of the hypothalamic-pituitary-adrenal axis. Clinical manifestations may include mineralocorticoid and/or androgen excess without manifestations of Cushing syndrome. At a cellular level, glucocorticoid actions are mediated by the nuclear glucocorticoid receptor encoded by the gene. To date, only 33 glucocorticoid receptor loss-of-function pathogenic variants have been associated with glucocorticoid resistance syndrome. The gene has 2 known disease-causing mechanisms: haploinsufficiency and negative dominance. We describe a mother and her son with a mild hyperandrogenic phenotype and a novel genetic variant of the gene predicting a truncated protein and causing glucocorticoid resistance syndrome. To date, no accurate genotype-phenotype correlation has been found.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10759794PMC
http://dx.doi.org/10.1210/jcemcr/luad153DOI Listing

Publication Analysis

Top Keywords

glucocorticoid resistance
16
resistance syndrome
16
glucocorticoid receptor
12
glucocorticoid
8
gene glucocorticoid
8
syndrome
5
syndrome cases
4
cases novel
4
novel pathogenic
4
pathogenic variant
4

Similar Publications

Serum CXCL-1 as a predictive biomarker for glucocorticoid resistance in adenoids of patients with adenoid hypertrophy.

Eur Arch Otorhinolaryngol

December 2024

Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan, 430060, China.

Purpose: The objective of this study was to elucidate the relationship between adenoid hypertrophy (AH) and glucocorticoid resistance, and to investigate the potential reasons for the suboptimal therapeutic response to intranasal glucocorticoids (INS) in pediatric patients with AH.

Methods: The present study enrolled a cohort of 110 patients diagnosed with AH, all of whom underwent adenoidectomy at Renmin Hospital of Wuhan University between June 2023 and September 2023. Immunohistochemistry and real-time quantitative polymerase chain reaction (RT-qPCR) were employed to assess the levels of inflammatory cytokines, and glucocorticoid receptors (GR, including GRα and GRβ) in adenoidal tissues.

View Article and Find Full Text PDF

To investigate the protective effects and underlying mechanisms of Qin-Zhu-Liang-Xue decoction (QZLX) in atopic dermatitis (AD) and glucocorticoid resistance, we conducted a single-blinded, randomized controlled clinical trial to evaluate the efficacy and safety of this concoction. Network pharmacology analysis was performed and validated through clinical studies. The efficacy, safety, and mechanism of action of QZLX and glucocorticoid receptor (GR) α recombinant protein were assessed in AD mice induced by 2,4-dinitrofluorobenzene (DNFB).

View Article and Find Full Text PDF
Article Synopsis
  • Primary generalized glucocorticoid resistance syndrome (GGRS) is a rare condition linked to a mutation in the NR3C1 gene, specifically a missense variant affecting the Glucocorticoid Receptor's DNA Binding Domain.
  • A case study detailed a 59-year-old man with high cortisol levels and a misdiagnosis of Cushing disease, ultimately leading to a correct diagnosis of GGRS at age 68.
  • Functional tests on the identified gene variant indicated it had significantly reduced transcriptional activity, emphasizing the need for increased awareness of GGRS to prevent misdiagnosis and harmful treatments.
View Article and Find Full Text PDF

Objectives: To investigate the expression of hypoxia-inducible factor-1α (HIF-1α) in patients with refractory sudden sensorineural hearing loss (SSNHL).

Material And Methods: Thirty patients with refractory SSNHL were treated with intratympanic methylprednisolone perfusion (IMP) for 10 days. Expression of HIF-1α and histone deacetylase 2 (HDAC2) was evaluated in peripheral blood mononuclear cells (PBMCs) and .

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!